Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22
Mumbai (Maharashtra) [India], February 12 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a global innovation-driven pharmaceutical company, today announced its financial results for the third quarter ended December 31, 2021.